Incretyxbio is leading the way in developing solutions for getting drugs delivered across the blood-brain-barrier and directly into the brain. It has a pre-clinical GLP-1 program with preferential brain delivery of existing GLP-1 drugs at lower doses that mitigate side effects but maintain efficacy. The company is also sponsoring three clinical trials for its patented direct nose-to-brain delivery of NAC (N-acetylcysteine) to treat Parkinson’s Disease. See Overview.